News

Yahoo Finance1y
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results
REDWOOD CITY, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the ...
Nasdaq4y
Soleno (SLNO) to report Q2 Earnings: What's in the Cards?
Soleno Therapeutics, Inc. SLNO will provide updates on its pipeline candidates when it releases second-quarter 2020 results. The company has a mixed track record, delivering an earnings beat in ...
Business Insider11mon
Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome
REDWOOD CITY, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing ...
Benzinga.com2mon
Soleno Shares Are Up Today: What's Going On?
Soleno Therapeutics shares jumped 37.2% after securing FDA approval for Vykat XR, its first commercial drug for treating hyperphagia. The approval was based on Phase 3 trial data showing ...
Benzinga.com1y
Soleno Therapeutics' Study Outcome Bolsters Confidence In PWS Treatment
Earlier on Tuesday, Soleno Therapeutics Inc SLNO released top-line results from the randomized withdrawal period of Study C602, a long-term treatment study of DCCR (Diazoxide Choline ...